{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:07:12Z","timestamp":1790701632021,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T00:00:00Z","timestamp":1671494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100018617","name":"Liaoning Revitalization Talents Program","doi-asserted-by":"publisher","award":["XLYC1905004"],"award-info":[{"award-number":["XLYC1905004"]}],"id":[{"id":"10.13039\/501100018617","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenyang High-level Innovation Talents Plan","award":["RC190403"],"award-info":[{"award-number":["RC190403"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00432-022-04513-0","type":"journal-article","created":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T06:02:51Z","timestamp":1671516171000},"page":"2699-2708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["The negative impact of opioids on cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"149","author":[{"given":"Mingguang","family":"Ju","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daosong","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4244-6855","authenticated-orcid":false,"given":"Kai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,20]]},"reference":[{"key":"4513_CR1","doi-asserted-by":"publisher","first-page":"9120162","DOI":"10.1155\/2021\/9120162","volume":"2021","author":"MD Angrish","year":"2021","unstructured":"Angrish MD, Agha A, Pezo RC (2021) Association of antibiotics and other drugs with clinical outcomes in metastatic melanoma patients treated with immunotherapy. J Skin Cancer 2021:9120162. https:\/\/doi.org\/10.1155\/2021\/9120162","journal-title":"J Skin Cancer"},{"key":"4513_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-066375","volume":"377","author":"N Avery","year":"2022","unstructured":"Avery N, McNeilage AG, Stanaway F, Ashton-James CE, Blyth FM, Martin R, Gholamrezaei A, Glare P (2022) Efficacy of interventions to reduce long term opioid treatment for chronic non-cancer pain: systematic review and meta-analysis. BMJ 377:e066375. https:\/\/doi.org\/10.1136\/bmj-2021-066375","journal-title":"BMJ"},{"key":"4513_CR3","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","volume":"51","author":"MH van den Beuken-van Everdingen","year":"2016","unstructured":"van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ (2016) Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 51:1070-1090.e1079. https:\/\/doi.org\/10.1016\/j.jpainsymman.2015.12.340","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"4513_CR4","doi-asserted-by":"publisher","first-page":"S713","DOI":"10.1016\/j.jtho.2019.08.1520","volume":"14","author":"P Bironzo","year":"2019","unstructured":"Bironzo P, Pignataro D, Audisio M, Tagliamento M, Novello S (2019) P2.04\u201315 Association between opioids and outcome of 1st line immunotherapy in advanced nsclc patients: a retrospective evaluation. J Thoracic Oncol 14(10):S713","journal-title":"J Thoracic Oncol"},{"key":"4513_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12967-021-02784-8","volume":"19","author":"A Botticelli","year":"2021","unstructured":"Botticelli A, Cirillo A, Pomati G, Cerbelli B, Scagnoli S, Roberto M, Gelibter A, Mammone G, Calandrella ML, Cerbelli E, Di Pietro FR, De Galitiis F, Lanzetta G, Cortesi E, Mezi S, Marchetti P (2021) The role of opioids in cancer response to immunotherapy. J Transl Med 19:119. https:\/\/doi.org\/10.1186\/s12967-021-02784-8","journal-title":"J Transl Med"},{"key":"4513_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1146\/annurev-biochem-061620-044044","volume":"90","author":"T Che","year":"2021","unstructured":"Che T, Roth BL (2021) Structural insights accelerate the discovery of opioid alternatives. Annu Rev Biochem 90:739\u2013761. https:\/\/doi.org\/10.1146\/annurev-biochem-061620-044044","journal-title":"Annu Rev Biochem"},{"key":"4513_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001361","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Bisonni R, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Marconcini R, Vitale MG, Nicolardi L, Chiari R, Bareggi C, Nigro O, Tuzi A, De Tursi M, Petragnani N, Pala L, Bracarda S, Macrini S, Inno A, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Pinato DJ, Porzio G, Ficorella C, Ascierto PA (2020) Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001361","journal-title":"J Immunother Cancer"},{"key":"4513_CR8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa L, Routy B, Thomas AM, Iebba V, Zalcman G, Friard S, Mazieres J, Audigier-Valette C, Moro-Sibilot D, Goldwasser F, Silva CAC, Terrisse S, Bonvalet M, Scherpereel A, Pegliasco H, Richard C, Ghiringhelli F, Elkrief A, Desilets A, Blanc-Durand F, Cumbo F, Blanco A, Boidot R, Chevrier S, Daill\u00e8re R, Kroemer G, Alla L, Pons N, Le Chatelier E, Galleron N, Roume H, Dubuisson A, Bouchard N, Messaoudene M, Drubay D, Deutsch E, Barlesi F, Planchard D, Segata N, Martinez S, Zitvogel L, Soria JC, Besse B (2022) Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med 28:315\u2013324. https:\/\/doi.org\/10.1038\/s41591-021-01655-5","journal-title":"Nat Med"},{"key":"4513_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2217\/imt-2019-0064","volume":"12","author":"S Gandhi","year":"2020","unstructured":"Gandhi S, Pandey M, Ammannagari N, Wang C, Bucsek MJ, Hamad L, Repasky E, Ernstoff MS (2020) Impact of concomitant medication use and immune-related adverse events on response to immune checkpoint inhibitors. Immunotherapy 12:141\u2013149. https:\/\/doi.org\/10.2217\/imt-2019-0064","journal-title":"Immunotherapy"},{"key":"4513_CR10","doi-asserted-by":"publisher","first-page":"175883592110005","DOI":"10.1177\/17588359211000591","volume":"13","author":"L Gaucher","year":"2021","unstructured":"Gaucher L, Adda L, S\u00e9journ\u00e9 A, Joachim C, Guillaume C, Poulet C, Liabeuf S, Gras-Champel V, Masmoudi K, Houessinon A, Bennis Y, Batteux B (2021) Associations between dysbiosis-inducing drugs, overall survival and tumor response in patients treated with immune checkpoint inhibitors. Ther Adv Med Oncol 13:17588359211000592. https:\/\/doi.org\/10.1177\/17588359211000591","journal-title":"Ther Adv Med Oncol"},{"key":"4513_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11523-019-00665-1","volume":"14","author":"P Grivas","year":"2019","unstructured":"Grivas P, Monk BJ, Petrylak D, Reck M, Foley G, Guenther S, Hennessy D, Makris C, Moehler M (2019) Immune checkpoint inhibitors as switch or continuation maintenance therapy in solid tumors: rationale and current state. Target Oncol 14:505\u2013525. https:\/\/doi.org\/10.1007\/s11523-019-00665-1","journal-title":"Target Oncol"},{"key":"4513_CR12","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee (2018). In: WHO Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents. World Health Organization \u00a9 World Health Organization 2018., Geneva,"},{"key":"4513_CR13","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1001\/jamaoncol.2019.5233","volume":"6","author":"Y He","year":"2020","unstructured":"He Y, Guo X, May BH, Zhang AL, Liu Y, Lu C, Mao JJ, Xue CC, Zhang H (2020) Clinical evidence for association of acupuncture and acupressure with improved cancer pain: a systematic review and meta-analysis. JAMA Oncol 6:271\u2013278. https:\/\/doi.org\/10.1001\/jamaoncol.2019.5233","journal-title":"JAMA Oncol"},{"key":"4513_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring Inconsistency in Meta-Analyses. BMJ 327:557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"key":"4513_CR15","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrd.2015.35","volume":"15","author":"A Hoos","year":"2016","unstructured":"Hoos A (2016) Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 15:235\u2013247. https:\/\/doi.org\/10.1038\/nrd.2015.35","journal-title":"Nat Rev Drug Discov"},{"key":"4513_CR16","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jtho.2022.02.003","volume":"17","author":"AM Hopkins","year":"2022","unstructured":"Hopkins AM, Badaoui S, Kichenadasse G, Karapetis CS, McKinnon RA, Rowland A, Sorich MJ (2022) Efficacy of Atezolizumab in patients with advanced NSCLC receiving concomitant antibiotic or proton pump inhibitor treatment: pooled analysis of five randomized control trials. J Thorac Oncol 17:758\u2013767. https:\/\/doi.org\/10.1016\/j.jtho.2022.02.003","journal-title":"J Thorac Oncol"},{"key":"4513_CR17","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1200\/jco.18.01567","volume":"37","author":"R Huang","year":"2019","unstructured":"Huang R, Jiang L, Cao Y, Liu H, Ping M, Li W, Xu Y, Ning J, Chen Y, Wang X (2019) Comparative efficacy of therapeutics for chronic cancer pain: a bayesian network meta-analysis. J Clin Oncol 37:1742\u20131752. https:\/\/doi.org\/10.1200\/jco.18.01567","journal-title":"J Clin Oncol"},{"key":"4513_CR18","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s12094-019-02282-w","volume":"22","author":"A Iglesias-Santamar\u00eda","year":"2020","unstructured":"Iglesias-Santamar\u00eda A (2020) Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer. Clin Transl Oncol 22:1481\u20131490. https:\/\/doi.org\/10.1007\/s12094-019-02282-w","journal-title":"Clin Transl Oncol"},{"key":"4513_CR19","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1016\/s0140-6736(17)32513-8","volume":"391","author":"FM Knaul","year":"2018","unstructured":"Knaul FM, Farmer PE, Krakauer EL, De Lima L, Bhadelia A, Jiang Kwete X, Arreola-Ornelas H, G\u00f3mez-Dant\u00e9s O, Rodriguez NM, Alleyne GAO, Connor SR, Hunter DJ, Lohman D, Radbruch L, Madrigal DRS, M, Atun R, Foley KM, Frenk J, Jamison DT, Rajagopal MR, (2018) Alleviating the access abyss in palliative care and pain relief-an imperative of universal health coverage: the lancet commission report. Lancet 391:1391\u20131454. https:\/\/doi.org\/10.1016\/s0140-6736(17)32513-8","journal-title":"Lancet"},{"key":"4513_CR20","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","volume":"157","author":"M Kostine","year":"2021","unstructured":"Kostine M, Mauric E, Tison A, Barnetche T, Barre A, Nikolski M, Rouxel L, Dutriaux C, Dousset L, Prey S, Beylot-Barry M, Seneschal J, Veillon R, Vergnenegre C, Daste A, Domblides C, Sionneau B, Gross-Goupil M, Ravaud A, Forcade E, Schaeverbeke T (2021) Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer 157:474\u2013484. https:\/\/doi.org\/10.1016\/j.ejca.2021.08.036","journal-title":"Eur J Cancer"},{"key":"4513_CR21","doi-asserted-by":"publisher","first-page":"4445","DOI":"10.1002\/jcp.30161","volume":"236","author":"H Lu","year":"2021","unstructured":"Lu H, Zhang H, Weng ML, Zhang J, Jiang N, Cata JP, Ma D, Chen WK, Miao CH (2021) Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer. J Cell Physiol 236:4445\u20134454. https:\/\/doi.org\/10.1002\/jcp.30161","journal-title":"J Cell Physiol"},{"key":"4513_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1001\/jamasurg.2021.6210","volume":"157","author":"PE Macintyre","year":"2022","unstructured":"Macintyre PE, Quinlan J, Levy N, Lobo DN (2022) Current issues in the use of opioids for the management of postoperative pain: a review. JAMA Surg 157:158\u2013166. https:\/\/doi.org\/10.1001\/jamasurg.2021.6210","journal-title":"JAMA Surg"},{"key":"4513_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.bbi.2019.10.011","volume":"83","author":"DP Maher","year":"2020","unstructured":"Maher DP, Walia D, Heller NM (2020) Morphine decreases the function of primary human natural killer cells by both TLR4 and opioid receptor signaling. Brain Behav Immun 83:298\u2013302. https:\/\/doi.org\/10.1016\/j.bbi.2019.10.011","journal-title":"Brain Behav Immun"},{"key":"4513_CR24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s10753-016-0310-x","volume":"39","author":"M Mao","year":"2016","unstructured":"Mao M, Qian Y, Sun J (2016) Morphine suppresses t helper lymphocyte differentiation to th1 type through pi3k\/akt pathway. Inflammation 39:813\u2013821. https:\/\/doi.org\/10.1007\/s10753-016-0310-x","journal-title":"Inflammation"},{"key":"4513_CR25","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1111\/1759-7714.14001","volume":"12","author":"K Miura","year":"2021","unstructured":"Miura K, Sano Y, Niho S, Kawasumi K, Mochizuki N, Yoh K, Matsumoto S, Zenke Y, Ikeda T, Nosaki K, Kirita K, Udagawa H, Goto K, Kawasaki T, Hanada K (2021) Impact of concomitant medication on clinical outcomes in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study. Thorac Cancer 12:1983\u20131994. https:\/\/doi.org\/10.1111\/1759-7714.14001","journal-title":"Thorac Cancer"},{"key":"4513_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"key":"4513_CR27","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","volume":"5","author":"DJ Pinato","year":"2019","unstructured":"Pinato DJ, Howlett S, Ottaviani D, Urus H, Patel A, Mineo T, Brock C, Power D, Hatcher O, Falconer A, Ingle M, Brown A, Gujral D, Partridge S, Sarwar N, Gonzalez M, Bendle M, Lewanski C, Newsom-Davis T, Allara E, Bower M (2019) Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer. JAMA Oncol 5:1774\u20131778. https:\/\/doi.org\/10.1001\/jamaoncol.2019.2785","journal-title":"JAMA Oncol"},{"key":"4513_CR28","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"key":"4513_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3322\/caac.21453","volume":"68","author":"BM Scarborough","year":"2018","unstructured":"Scarborough BM, Smith CB (2018) Optimal pain management for patients with cancer in the modern era. CA Cancer J Clin 68:182\u2013196. https:\/\/doi.org\/10.3322\/caac.21453","journal-title":"CA Cancer J Clin"},{"key":"4513_CR30","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14182","author":"M Svaton","year":"2020","unstructured":"Svaton M, Zemanova M, Zemanova P, Kultan J, Fischer O, Skrickova J, Jakubikova L, Cernovska M, Hrnciarik M, Jirousek M, Krejci J, Krejci D, Bilek O, Blazek J, Hurdalkova K, Barinova M, Melichar B (2020) Impact of concomitant medication administered at the time of initiation of nivolumab therapy on outcome in non-small cell lung cancer. Anticancer Res. https:\/\/doi.org\/10.21873\/anticanres.14182","journal-title":"Anticancer Res"},{"issue":"10","key":"4513_CR31","doi-asserted-by":"publisher","first-page":"S390","DOI":"10.1016\/j.jtho.2019.08.792","volume":"14","author":"Y Taniguchi","year":"2019","unstructured":"Taniguchi Y, Tamiya A, Isa S, Nakahama K, Atagi S (2019) P101\u201377 impact of oral drugs on the prognosis of non-small-cell lung cancer patients treated with Nivolumab. J Thoracic Oncol 14(10):S390","journal-title":"J Thoracic Oncol"},{"key":"4513_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjspcare-2020-002480","author":"Y Taniguchi","year":"2020","unstructured":"Taniguchi Y, Tamiya A, Matsuda Y, Adachi Y, Enomoto T, Azuma K, Kouno S, Tokoro A, Atagi S (2020) Opioids impair Nivolumab outcomes: a retrospective propensity score analysis in non-small-cell lung cancer. BMJ Support Palliat Care. https:\/\/doi.org\/10.1136\/bmjspcare-2020-002480","journal-title":"BMJ Support Palliat Care"},{"key":"4513_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. https:\/\/doi.org\/10.1186\/1745-6215-8-16","journal-title":"Trials"},{"key":"4513_CR34","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1182\/blood.2019003526","volume":"135","author":"L Vercellino","year":"2020","unstructured":"Vercellino L, Cottereau A-S, Casasnovas O, Tilly H, Feugier P, Chartier L, Fruchart C, Roulin L, Oberic L, Pica GM, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O, Sebban C, L\u00f3pez-Guillermo A, Sanhes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Briere J, Salles G, Gaulard P, Meignan M, Thieblemont C (2020) High total metabolic tumor volume at baseline predicts survival independent of response to therapy. Blood 135:1396\u20131405. https:\/\/doi.org\/10.1182\/blood.2019003526","journal-title":"Blood"},{"key":"4513_CR35","unstructured":"Wells GA, Shea BJ, O'Connell D, Peterson J, Tugwell P (2000) The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis."},{"key":"4513_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.757993","volume":"11","author":"A Xiong","year":"2021","unstructured":"Xiong A, Wang J, Zhou C (2021) Immunotherapy in the first-line treatment of NSCLC: current status and future directions in china. Front Oncol 11:757993. https:\/\/doi.org\/10.3389\/fonc.2021.757993","journal-title":"Front Oncol"},{"key":"4513_CR37","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9293704","author":"R Zaj\u0105czkowska","year":"2018","unstructured":"Zaj\u0105czkowska R, Leppert W, Mika J, Kocot-K\u0119pska M, Woro\u0144 J, Wrzosek A, Wordliczek J (2018) Perioperative immunosuppression and risk of cancer progression: the impact of opioids on pain management. Pain Res Manag. https:\/\/doi.org\/10.1155\/2018\/9293704","journal-title":"Pain Res Manag"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04513-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04513-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04513-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,25]],"date-time":"2023-04-25T10:11:50Z","timestamp":1682417510000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04513-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,20]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["4513"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04513-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,20]]},"assertion":[{"value":"15 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NonE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}